Alvotech
Alvotech (ALVO) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · ALVO · as of Jun 8, 2026
Key Statistics
Explore Alvotech Data
alvo stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 5 · Buy rate: 40.0%
The ALVO analyst consensus is Buy, based on ratings from 5 Wall Street analysts over the past 3 months. The average 12-month price target is $5.00, representing +41.24% upside from the current price of $3.54.
Competitors & Peers
alvo competitorsALVO
AMPH
BHVN
COLL
EVO
HROWStock Performance
Full HistoryAbout Alvotech
Alvotech through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders…
what is alvotech · alvo stock overview · alvotech company profile · who is alvotech ceo · alvo NASDAQ · alvotech headquarters · alvotech business segments
About Stock Overview & Key Data
Alvotech (ALVO) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry, listed on NASDAQ since Jun 16, 2022. As of the latest trading session, ALVO stock price is $3.54, with a market capitalization of $1.1B. The stock has returned -66.70% over the past 12 months and -30.99% year-to-date.
According to 5 Wall Street analysts, the consensus rating for Alvotech stock is Buy, with an average 12-month price target of $5.00. In fiscal year 2025, Alvotech reported revenue of $586.3M and net income of $27.9M. For detailed data — including Alvotech revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Alvotech (ALVO) stock price is $3.54. The stock is traded on NASDAQ under the ticker symbol ALVO. The 52-week range is $2.94 – $11.12.